Post hoc analyses revealed that these benefits included significant reductions of visceral (mesenteric and retroperitoneal) adipose depot weights, fasting insulin concentrations (from 3 to 6 months) and an index of insulin resistance (QUICKI), as well as lower fasting plasma TG and increases of pancreatic islet area and insulin content. Here, INS is linked to Insulin resistance.